PacBio Director Christopher M. Smith Resigns Abruptly, No Reason Given
PACB sits 48% above its 52-week low of $1.09.
Summary
Director Christopher M. Smith resigned from PacBio's board effective July 8, 2026. No reason was disclosed, and no replacement was named. The departure comes amid a period of improving financials — the company recently narrowed its quarterly net loss to $8.3 million — but the sudden exit without explanation raises governance questions. The board now has a vacancy to fill, and investors will watch for any further departures or disclosures.
At the time of this announcement, PACB was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $500.1M. The 52-week trading range was $1.09 to $2.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.